Navigation Links
Neurological Wellness Center Criticizes the U.S. Patent Office for Issuing a Patent for an Injection Site on the Human Body

(PRWEB) February 13, 2013

Unlike Dr. Burzenski’s antineoplastons, the drug used to effectively treat Alzheimer’s, Stroke and Traumatic Brain Injury is available at your local pharmacy. This drug, Enbrel, is used by over 400,000 Americans as a treatment for rheumatoid arthritis. However, for Enbrel to effectively treat Alzheimer’s, Stroke and TBI, it must be administered to the back of the neck precisely between cervical vertebrae C-5 and C-6. Only in the United States does a patent of an injection site on the human body have legal standing in a court of law.

Since 2010 Neurological Wellness Center has been providing hands-on individual instruction on the administration of this perispinal injection at their headquarters in Managua Nicaragua. Visit

For many, flying to Managua Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 37-page e-book are now available online at

Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.

Presently all FDA-approved drugs for the treatment of Alzheimer’s disease simply slow the rate of disease progression. Enbrel, when administered to the area between cervical vertebrae C-5 and C-6, enables the recovery of cognitive function, reversing impairments to memory, resulting in an improved sense of well-being and more engaging social interaction. A portion of those people treated with perispinal Enbrel injections will go on to live normal lives and eventually die of causes unrelated to Alzheimer’s disease.

Pharmaceutical companies generate billions of dollars annually selling drugs approved for the treatment of Alzheimer’s disease. The U.S. patent office, by granting patent 7214658, effectively makes it illegal for American physicians to treat Alzheimer’s disease by administering Enbrel perispinally. A physician who administers a subcutaneous injection of any drug to this area of the neck is in violation of patent 7214658. Administering such an injection exposes the physician to litigation and the prospect of being forced to pay a hefty fine for patent infringement.

The recent publication of an observational study involving 629 stroke and traumatic brain injury patients treated with perispinal Enbrel injections demonstrates the potential of perispinal Enbrel treatments to effectively address the unmet medical needs of millions of people living with impairments caused by stroke or TBI. Perispinal Enbrel’s efficacy extends to persons treated years after suffering a stroke or TBI.

"The U.S. Patent Office’s issuance of 7214658 not only serves to limit access to an alternative to the minimally effective Alzheimer’s treatment pharmaceuticals that are currently available, but importantly serves to limit access to a treatment for stroke and TBI, for which there is presently no other treatment available." Dr. Augusto Ramirez.

To enroll in a hands-on instructional course on perispinal injections visit

To purchase an instructional video and e-book on administering perispinal injections visit:

To purchase Enbrel at the lowest prices in North America visit:
To watch the movie Burzynski free visit:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Subcortical damage is primary cause of neurological deficits after awake craniotomy
2. New technology may help doctors monitor concussions, aging, and neurological function
3. NIH clinical trial begins for treatment of rare, fatal neurological disorder
4. Neurological Wellness Center Posts 700% Sales Increase in 2012; Enters Strategic Alliance with Enbrel Buyer's Club to Provide Low Cost Enbrel
5. Neurological Wellness Center Pays Tribute to Newly Released Study Announcing TBI Treatment Breakthrough
6. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
7. University Hospitals Neurological Institute to present 6th International 2013 Epilepsy Colloquium
8. Cedars-Sinai physician-scientist awarded $3M to study most common inherited neurological disorder
9. The hidden disorder: Unique treatment proposed for childrens neurological disorder
10. New national clinical trials network for neurological disorders to foster cutting-edge treatments
11. Kids With Neurological Conditions at Higher Risk of Flu Death: CDC
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday 27 Oct 2015, ... educate the personnel on spinal decompression therapy and offer his professional help. , ... The benefits come from creating negative intradiscal pressure which is conducive to retraction ...
(Date:12/1/2015)... ... 01, 2015 , ... World Patent Marketing , a vertically integrated ... allows for easier packing and organizing of items into one big, portable jar. , ... Cooper, CEO and Creative Director of World Patent Marketing and Desa Industries Inc ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article ... a discrimination claim against the U.S. Department of Health and Human Services, claiming that ... (ACA) plans are breaking the clause in the law prohibiting the denial of coverage ...
(Date:12/1/2015)... Los Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... the United States, today announced that its iconic bottle has won top honors in ... drinks category. The Company also announced that it has been selected as a ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)...  Six months of adjunctive metformin therapy does not improve ... to new research from T1D Exchange and funded ... beneficial effect on measures of obesity, including weight and BMI. ... Journal of the American Medical Association , are from the ... on overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
Breaking Medicine Technology: